MAPT and Alzheimer disease: The criteria encompass cognitive impairment with additional biomarkers of reduced CSF amyloid beta (Aβ42) or increased cortical Aβ plaques, increased CSF tau levels, temporoparietal [18F]‐fluorodeoxyglucose‐positron‐emission tomography (FDG‐PET) hypometabolism, and atrophy to medial temporal structures measured with MRI, as criteria contributing to a MCI‐AD diagnosis.